MX2021002509A - 1h-indazol carboxamidas como inhibidores de proteina cinasa de interaccion con receptor 1 (ripk1). - Google Patents
1h-indazol carboxamidas como inhibidores de proteina cinasa de interaccion con receptor 1 (ripk1).Info
- Publication number
- MX2021002509A MX2021002509A MX2021002509A MX2021002509A MX2021002509A MX 2021002509 A MX2021002509 A MX 2021002509A MX 2021002509 A MX2021002509 A MX 2021002509A MX 2021002509 A MX2021002509 A MX 2021002509A MX 2021002509 A MX2021002509 A MX 2021002509A
- Authority
- MX
- Mexico
- Prior art keywords
- ripk1
- inhibitors
- receptor
- protein kinase
- interacting protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730602P | 2018-09-13 | 2018-09-13 | |
| PCT/US2019/050719 WO2020056072A1 (en) | 2018-09-13 | 2019-09-12 | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002509A true MX2021002509A (es) | 2021-04-28 |
Family
ID=68073171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002509A MX2021002509A (es) | 2018-09-13 | 2019-09-12 | 1h-indazol carboxamidas como inhibidores de proteina cinasa de interaccion con receptor 1 (ripk1). |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12172975B2 (https=) |
| EP (1) | EP3849968B1 (https=) |
| JP (1) | JP7599411B2 (https=) |
| KR (1) | KR102906523B1 (https=) |
| CN (1) | CN112673000B (https=) |
| AU (1) | AU2019337612A1 (https=) |
| BR (1) | BR112021004385A2 (https=) |
| CA (1) | CA3112735A1 (https=) |
| EA (1) | EA202190718A1 (https=) |
| ES (1) | ES2936481T3 (https=) |
| IL (1) | IL281370A (https=) |
| MX (1) | MX2021002509A (https=) |
| SG (1) | SG11202102405YA (https=) |
| WO (1) | WO2020056072A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE058292T2 (hu) | 2017-10-30 | 2022-07-28 | Bristol Myers Squibb Co | Aminoimidazopiridazinok mint kináz inhibitorok |
| CN112262139B (zh) | 2018-01-26 | 2023-07-25 | 百时美施贵宝公司 | 作为激酶抑制剂的氨基吡咯并三嗪 |
| AU2019339355A1 (en) | 2018-09-13 | 2021-05-13 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| ES2969756T3 (es) * | 2019-10-03 | 2024-05-22 | Bristol Myers Squibb Co | Indazol carboxamidas como inhibidores de cinasas |
| EP4214207A4 (en) | 2020-09-15 | 2024-10-02 | 1st Biotherapeutics, Inc. | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS |
| AR123793A1 (es) | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
| WO2025106362A1 (en) * | 2023-11-16 | 2025-05-22 | Merck Sharp & Dohme Llc | Ripk1 inhibitors and methods of use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4836788B2 (ja) | 2003-07-23 | 2011-12-14 | エグゼリクシス， インコーポレイテッド | 未分化リンパ腫キナーゼ変調因子及びその使用法 |
| RU2418797C2 (ru) | 2004-12-22 | 2011-05-20 | Мемори Фармасьютиклз Корпорейшн | Лиганды никотинового рецептора альфа-7, их получение и применение |
| UA92083C2 (ru) | 2006-05-19 | 2010-09-27 | Эбботт Леборетриз | Азабициклические алкановые производные, замещенные конденсированным бициклогетероциклом |
| KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| WO2010068287A2 (en) | 2008-12-11 | 2010-06-17 | Angion Biomedica Corp. | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| EA020017B1 (ru) | 2009-04-30 | 2014-08-29 | Новартис Аг | Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ |
| US8455516B2 (en) | 2010-01-15 | 2013-06-04 | Touro University | HIV-1 fusion inhibitors and methods |
| KR20130077390A (ko) * | 2011-12-29 | 2013-07-09 | 제이더블유중외제약 주식회사 | 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체 |
| RS54539B1 (sr) | 2012-02-21 | 2016-06-30 | Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A. | Upotreba 1h-indazol-3-karboksamidnih jedinjenja kao inhibitora kinaze 3-beta glikogen sintetaze |
| CA2860250C (en) | 2012-02-21 | 2020-11-10 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| WO2014047024A1 (en) | 2012-09-18 | 2014-03-27 | Bristol-Myers Squibb Company | Iap antagonists |
| CN104781251B (zh) * | 2012-11-08 | 2016-12-14 | 百时美施贵宝公司 | 可作为激酶调节剂的经双环杂环取代的吡啶基化合物 |
| MX2016012208A (es) | 2014-03-20 | 2017-01-26 | Samumed Llc | Indazol-3-carboxamidas 5-substituidas y preparacion y uso de las mismas. |
| EP3463355B1 (en) | 2016-05-26 | 2024-08-28 | Sonic Master Limited | Modulators of dux4 for regulation of muscle function |
| MA47460A (fr) | 2017-02-13 | 2019-12-18 | Bristol Myers Squibb Co | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase |
| HUE058292T2 (hu) | 2017-10-30 | 2022-07-28 | Bristol Myers Squibb Co | Aminoimidazopiridazinok mint kináz inhibitorok |
| CN112262139B (zh) | 2018-01-26 | 2023-07-25 | 百时美施贵宝公司 | 作为激酶抑制剂的氨基吡咯并三嗪 |
| AU2019339355A1 (en) | 2018-09-13 | 2021-05-13 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| ES2969756T3 (es) | 2019-10-03 | 2024-05-22 | Bristol Myers Squibb Co | Indazol carboxamidas como inhibidores de cinasas |
-
2019
- 2019-09-12 KR KR1020217010498A patent/KR102906523B1/ko active Active
- 2019-09-12 BR BR112021004385-3A patent/BR112021004385A2/pt not_active Application Discontinuation
- 2019-09-12 US US17/274,220 patent/US12172975B2/en active Active
- 2019-09-12 SG SG11202102405YA patent/SG11202102405YA/en unknown
- 2019-09-12 MX MX2021002509A patent/MX2021002509A/es unknown
- 2019-09-12 EA EA202190718A patent/EA202190718A1/ru unknown
- 2019-09-12 ES ES19779240T patent/ES2936481T3/es active Active
- 2019-09-12 WO PCT/US2019/050719 patent/WO2020056072A1/en not_active Ceased
- 2019-09-12 JP JP2021513958A patent/JP7599411B2/ja active Active
- 2019-09-12 AU AU2019337612A patent/AU2019337612A1/en not_active Abandoned
- 2019-09-12 EP EP19779240.1A patent/EP3849968B1/en active Active
- 2019-09-12 CA CA3112735A patent/CA3112735A1/en active Pending
- 2019-09-12 CN CN201980059445.8A patent/CN112673000B/zh active Active
-
2021
- 2021-03-09 IL IL281370A patent/IL281370A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3112735A1 (en) | 2020-03-19 |
| KR20210060517A (ko) | 2021-05-26 |
| CN112673000A (zh) | 2021-04-16 |
| US20220380335A1 (en) | 2022-12-01 |
| KR102906523B1 (ko) | 2025-12-30 |
| EP3849968A1 (en) | 2021-07-21 |
| SG11202102405YA (en) | 2021-04-29 |
| EP3849968B1 (en) | 2022-12-21 |
| ES2936481T3 (es) | 2023-03-17 |
| AU2019337612A1 (en) | 2021-05-13 |
| CN112673000B (zh) | 2024-10-18 |
| BR112021004385A2 (pt) | 2021-07-20 |
| JP7599411B2 (ja) | 2024-12-13 |
| US12172975B2 (en) | 2024-12-24 |
| JP2022500418A (ja) | 2022-01-04 |
| IL281370A (en) | 2021-04-29 |
| WO2020056072A1 (en) | 2020-03-19 |
| EA202190718A1 (ru) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002509A (es) | 1h-indazol carboxamidas como inhibidores de proteina cinasa de interaccion con receptor 1 (ripk1). | |
| MX2021002617A (es) | Indazol carboxamidas como inhibidores de cinasas. | |
| WO2019089442A8 (en) | Aminoimidazopyridazines as kinase inhibitors | |
| CY1124978T1 (el) | Αμινοτριαζολοπυριμιδινες ως αναστολεις κινασων | |
| CR20200373A (es) | Compuestos | |
| CL2022000448A1 (es) | Autoinyector (divisional solicitud no. 201903061) | |
| PH12018502136A1 (en) | Heterocyclic amides useful as protein modulators | |
| MY198004A (en) | Antitumoral compounds | |
| UY38837A (es) | Proceso de elaboración de moduladores de cftr | |
| SG10201805246XA (en) | Approximated parameter adaptation | |
| PH12020500655A1 (en) | Compounds | |
| EP4635568A3 (en) | Compounds, salts thereof and methods for treatment of diseases | |
| MX383935B (es) | Amidas heterocíclicas como inhibidores de cinasa. | |
| MX2022003769A (es) | Indazol carboxamidas como inhibidores de cinasas. | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| MY203303A (en) | Compounds | |
| EA202191519A1 (ru) | Модуляторы trex1 | |
| MX2019011774A (es) | N-(-1,3,4-oxadiazol-2-il)arilcarboxamidas sustituidas y su uso como herbicidas. | |
| MX388026B (es) | Compuestos y métodos para modular la tirosina cinasa de bruton. | |
| MX2019011116A (es) | Inhibidores de la tirosina quinasa de bruton. | |
| EP4364737A3 (en) | Triazolopyridinyl compounds as kinase inhibitors | |
| GEAP202415849A (en) | Crystalline salt forms of kinase inhibitor | |
| EA201992302A1 (ru) | Соединения, используемые в качестве ингибиторов alcat1 | |
| NZ742785A (en) | Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine |